Acid‐inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori‐negative healthy subjects
Background: Omeprazole 20 mg once daily (o.d.) and lansoprazole 30 mg o.d. have similar acid‐inhibitory effects in healthy Helicobacter pylori‐positive subjects. However, little is known about the acid‐inhibitory effects of the o.d. and twice daily (b.d.) doses in H. pylori‐negative subjects. Aim: T...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 1998-04, Vol.12 (4), p.329-335 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 335 |
|---|---|
| container_issue | 4 |
| container_start_page | 329 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 12 |
| creator | Geus Mulder Nicolai Boomgaard, D. M. Van Den Lamers |
| description | Background:
Omeprazole 20 mg once daily (o.d.) and lansoprazole 30 mg o.d. have similar acid‐inhibitory effects in healthy Helicobacter pylori‐positive subjects. However, little is known about the acid‐inhibitory effects of the o.d. and twice daily (b.d.) doses in H. pylori‐negative subjects.
Aim:
To compare the decrease in gastric acidity of omeprazole 20 mg (o.d. and b.d.) with lansoprazole 30 mg (o.d. and b.d.) in healthy H. pylori‐negative subjects on day 6–7 of dosing.
Methods:
A randomized, investigator‐blind, crossover study design was used. Intragastric pH was measured continuously with glass electrodes positioned in the gastric corpus. Sixteen H. pylori‐negative subjects, whose intragastric acidity fell below pH 4 for 70% of a 24‐h baseline period, were entered in the study.
Results:
Both dosing regimens of omeprazole and lansoprazole significantly increased median gastric pH and percentages of time above pH 4 during the entire 24‐h period, night‐ and daytime, compared to baseline. There were no significant differences in median gastric pH values or time above pH thresholds 3, 4 and 5 between the o.d. dosing regimens. During the night the percentage of time spent above pH 3 and 4 was significantly higher with omeprazole 20 mg b.d. than with lansoprazole 30 mg b.d.
Conclusions:
This comparative study demonstrates that daily doses of omeprazole 20 mg and lansoprazole 30 mg are equally effective in raising intragastric pH in H. pylori‐negative subjects on day 6 of dosing. During the night, omeprazole 20 mg b.d. provides superior gastric acid suppression compared to lansoprazole 30 mg b.d. |
| doi_str_mv | 10.1046/j.1365-2036.1998.00304.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80047621</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80047621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5084-7f575b40410075a63ee1ed6e8c883c241086f95f006e97a447022e272d8cf9703</originalsourceid><addsrcrecordid>eNqNkM-O0zAQxi0EWsrCIyD5gLgljJ3EfyQu1Qp2kVaCw3K2HGdMXdK42ClsOPEI-4w8CQktPXOyNd8338z8CKEMSga1eLMtWSWagkMlSqa1KgEqqMv7R2R1Fh6TFXChC65Y9ZQ8y3kLAEICvyAXWmiQnK3I17UL3e9fD2HYhDaMMU0UvUc3Zho9jTvcJ_sz9kjt0NHeDjn-K4SB3mAfXGytGzHR_dTHFOaoAb_YMXxHukHbj5uJ5kO7XRKfkyfe9hlfnN5L8vn9u7urm-L24_WHq_Vt4RpQdSF9I5u2hpoByMaKCpFhJ1A5pSrH57ISXjd-Pga1tHU9n8SRS94p57WE6pK8PubuU_x2wDyaXcgO-3l9jIdsFEAtBWezUR2NLsWcE3qzT2Fn02QYmIWz2ZoFp1lwmoWz-cvZ3M-tL08zDu0Ou3PjCeysvzrpNjvb-2QHF_LZxjkXUi-2t0fbj9Dj9N_jzfrT3fyp_gBsoZs2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80047621</pqid></control><display><type>article</type><title>Acid‐inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori‐negative healthy subjects</title><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Geus ; Mulder ; Nicolai ; Boomgaard, D. M. Van Den ; Lamers</creator><creatorcontrib>Geus ; Mulder ; Nicolai ; Boomgaard, D. M. Van Den ; Lamers</creatorcontrib><description>Background:
Omeprazole 20 mg once daily (o.d.) and lansoprazole 30 mg o.d. have similar acid‐inhibitory effects in healthy Helicobacter pylori‐positive subjects. However, little is known about the acid‐inhibitory effects of the o.d. and twice daily (b.d.) doses in H. pylori‐negative subjects.
Aim:
To compare the decrease in gastric acidity of omeprazole 20 mg (o.d. and b.d.) with lansoprazole 30 mg (o.d. and b.d.) in healthy H. pylori‐negative subjects on day 6–7 of dosing.
Methods:
A randomized, investigator‐blind, crossover study design was used. Intragastric pH was measured continuously with glass electrodes positioned in the gastric corpus. Sixteen H. pylori‐negative subjects, whose intragastric acidity fell below pH 4 for 70% of a 24‐h baseline period, were entered in the study.
Results:
Both dosing regimens of omeprazole and lansoprazole significantly increased median gastric pH and percentages of time above pH 4 during the entire 24‐h period, night‐ and daytime, compared to baseline. There were no significant differences in median gastric pH values or time above pH thresholds 3, 4 and 5 between the o.d. dosing regimens. During the night the percentage of time spent above pH 3 and 4 was significantly higher with omeprazole 20 mg b.d. than with lansoprazole 30 mg b.d.
Conclusions:
This comparative study demonstrates that daily doses of omeprazole 20 mg and lansoprazole 30 mg are equally effective in raising intragastric pH in H. pylori‐negative subjects on day 6 of dosing. During the night, omeprazole 20 mg b.d. provides superior gastric acid suppression compared to lansoprazole 30 mg b.d.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.1998.00304.x</identifier><identifier>PMID: 9690721</identifier><language>eng</language><publisher>Oxford UK: Blackwell Science Ltd</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Administration, Oral ; Adult ; Anti-Ulcer Agents - administration & dosage ; Anti-Ulcer Agents - pharmacology ; Anti-Ulcer Agents - therapeutic use ; Biological and medical sciences ; Cross-Over Studies ; Digestive system ; Double-Blind Method ; Gastric Acid - metabolism ; Helicobacter pylori ; Humans ; Lansoprazole ; Medical sciences ; Omeprazole - administration & dosage ; Omeprazole - analogs & derivatives ; Omeprazole - pharmacology ; Omeprazole - therapeutic use ; Pharmacology. Drug treatments</subject><ispartof>Alimentary pharmacology & therapeutics, 1998-04, Vol.12 (4), p.329-335</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5084-7f575b40410075a63ee1ed6e8c883c241086f95f006e97a447022e272d8cf9703</citedby><cites>FETCH-LOGICAL-c5084-7f575b40410075a63ee1ed6e8c883c241086f95f006e97a447022e272d8cf9703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2036.1998.00304.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2036.1998.00304.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2226791$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9690721$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geus</creatorcontrib><creatorcontrib>Mulder</creatorcontrib><creatorcontrib>Nicolai</creatorcontrib><creatorcontrib>Boomgaard, D. M. Van Den</creatorcontrib><creatorcontrib>Lamers</creatorcontrib><title>Acid‐inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori‐negative healthy subjects</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Background:
Omeprazole 20 mg once daily (o.d.) and lansoprazole 30 mg o.d. have similar acid‐inhibitory effects in healthy Helicobacter pylori‐positive subjects. However, little is known about the acid‐inhibitory effects of the o.d. and twice daily (b.d.) doses in H. pylori‐negative subjects.
Aim:
To compare the decrease in gastric acidity of omeprazole 20 mg (o.d. and b.d.) with lansoprazole 30 mg (o.d. and b.d.) in healthy H. pylori‐negative subjects on day 6–7 of dosing.
Methods:
A randomized, investigator‐blind, crossover study design was used. Intragastric pH was measured continuously with glass electrodes positioned in the gastric corpus. Sixteen H. pylori‐negative subjects, whose intragastric acidity fell below pH 4 for 70% of a 24‐h baseline period, were entered in the study.
Results:
Both dosing regimens of omeprazole and lansoprazole significantly increased median gastric pH and percentages of time above pH 4 during the entire 24‐h period, night‐ and daytime, compared to baseline. There were no significant differences in median gastric pH values or time above pH thresholds 3, 4 and 5 between the o.d. dosing regimens. During the night the percentage of time spent above pH 3 and 4 was significantly higher with omeprazole 20 mg b.d. than with lansoprazole 30 mg b.d.
Conclusions:
This comparative study demonstrates that daily doses of omeprazole 20 mg and lansoprazole 30 mg are equally effective in raising intragastric pH in H. pylori‐negative subjects on day 6 of dosing. During the night, omeprazole 20 mg b.d. provides superior gastric acid suppression compared to lansoprazole 30 mg b.d.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Administration, Oral</subject><subject>Adult</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Anti-Ulcer Agents - pharmacology</subject><subject>Anti-Ulcer Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cross-Over Studies</subject><subject>Digestive system</subject><subject>Double-Blind Method</subject><subject>Gastric Acid - metabolism</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Lansoprazole</subject><subject>Medical sciences</subject><subject>Omeprazole - administration & dosage</subject><subject>Omeprazole - analogs & derivatives</subject><subject>Omeprazole - pharmacology</subject><subject>Omeprazole - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM-O0zAQxi0EWsrCIyD5gLgljJ3EfyQu1Qp2kVaCw3K2HGdMXdK42ClsOPEI-4w8CQktPXOyNd8338z8CKEMSga1eLMtWSWagkMlSqa1KgEqqMv7R2R1Fh6TFXChC65Y9ZQ8y3kLAEICvyAXWmiQnK3I17UL3e9fD2HYhDaMMU0UvUc3Zho9jTvcJ_sz9kjt0NHeDjn-K4SB3mAfXGytGzHR_dTHFOaoAb_YMXxHukHbj5uJ5kO7XRKfkyfe9hlfnN5L8vn9u7urm-L24_WHq_Vt4RpQdSF9I5u2hpoByMaKCpFhJ1A5pSrH57ISXjd-Pga1tHU9n8SRS94p57WE6pK8PubuU_x2wDyaXcgO-3l9jIdsFEAtBWezUR2NLsWcE3qzT2Fn02QYmIWz2ZoFp1lwmoWz-cvZ3M-tL08zDu0Ou3PjCeysvzrpNjvb-2QHF_LZxjkXUi-2t0fbj9Dj9N_jzfrT3fyp_gBsoZs2</recordid><startdate>199804</startdate><enddate>199804</enddate><creator>Geus</creator><creator>Mulder</creator><creator>Nicolai</creator><creator>Boomgaard, D. M. Van Den</creator><creator>Lamers</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199804</creationdate><title>Acid‐inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori‐negative healthy subjects</title><author>Geus ; Mulder ; Nicolai ; Boomgaard, D. M. Van Den ; Lamers</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5084-7f575b40410075a63ee1ed6e8c883c241086f95f006e97a447022e272d8cf9703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Administration, Oral</topic><topic>Adult</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Anti-Ulcer Agents - pharmacology</topic><topic>Anti-Ulcer Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cross-Over Studies</topic><topic>Digestive system</topic><topic>Double-Blind Method</topic><topic>Gastric Acid - metabolism</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Lansoprazole</topic><topic>Medical sciences</topic><topic>Omeprazole - administration & dosage</topic><topic>Omeprazole - analogs & derivatives</topic><topic>Omeprazole - pharmacology</topic><topic>Omeprazole - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geus</creatorcontrib><creatorcontrib>Mulder</creatorcontrib><creatorcontrib>Nicolai</creatorcontrib><creatorcontrib>Boomgaard, D. M. Van Den</creatorcontrib><creatorcontrib>Lamers</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geus</au><au>Mulder</au><au>Nicolai</au><au>Boomgaard, D. M. Van Den</au><au>Lamers</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acid‐inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori‐negative healthy subjects</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>1998-04</date><risdate>1998</risdate><volume>12</volume><issue>4</issue><spage>329</spage><epage>335</epage><pages>329-335</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Background:
Omeprazole 20 mg once daily (o.d.) and lansoprazole 30 mg o.d. have similar acid‐inhibitory effects in healthy Helicobacter pylori‐positive subjects. However, little is known about the acid‐inhibitory effects of the o.d. and twice daily (b.d.) doses in H. pylori‐negative subjects.
Aim:
To compare the decrease in gastric acidity of omeprazole 20 mg (o.d. and b.d.) with lansoprazole 30 mg (o.d. and b.d.) in healthy H. pylori‐negative subjects on day 6–7 of dosing.
Methods:
A randomized, investigator‐blind, crossover study design was used. Intragastric pH was measured continuously with glass electrodes positioned in the gastric corpus. Sixteen H. pylori‐negative subjects, whose intragastric acidity fell below pH 4 for 70% of a 24‐h baseline period, were entered in the study.
Results:
Both dosing regimens of omeprazole and lansoprazole significantly increased median gastric pH and percentages of time above pH 4 during the entire 24‐h period, night‐ and daytime, compared to baseline. There were no significant differences in median gastric pH values or time above pH thresholds 3, 4 and 5 between the o.d. dosing regimens. During the night the percentage of time spent above pH 3 and 4 was significantly higher with omeprazole 20 mg b.d. than with lansoprazole 30 mg b.d.
Conclusions:
This comparative study demonstrates that daily doses of omeprazole 20 mg and lansoprazole 30 mg are equally effective in raising intragastric pH in H. pylori‐negative subjects on day 6 of dosing. During the night, omeprazole 20 mg b.d. provides superior gastric acid suppression compared to lansoprazole 30 mg b.d.</abstract><cop>Oxford UK</cop><pub>Blackwell Science Ltd</pub><pmid>9690721</pmid><doi>10.1046/j.1365-2036.1998.00304.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 1998-04, Vol.12 (4), p.329-335 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80047621 |
| source | MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles Administration, Oral Adult Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - pharmacology Anti-Ulcer Agents - therapeutic use Biological and medical sciences Cross-Over Studies Digestive system Double-Blind Method Gastric Acid - metabolism Helicobacter pylori Humans Lansoprazole Medical sciences Omeprazole - administration & dosage Omeprazole - analogs & derivatives Omeprazole - pharmacology Omeprazole - therapeutic use Pharmacology. Drug treatments |
| title | Acid‐inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori‐negative healthy subjects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A14%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acid%E2%80%90inhibitory%20effects%20of%20omeprazole%20and%20lansoprazole%20in%20Helicobacter%20pylori%E2%80%90negative%20healthy%20subjects&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Geus&rft.date=1998-04&rft.volume=12&rft.issue=4&rft.spage=329&rft.epage=335&rft.pages=329-335&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.1998.00304.x&rft_dat=%3Cproquest_cross%3E80047621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80047621&rft_id=info:pmid/9690721&rfr_iscdi=true |